Chinese medicines and bioactive compounds for treatment of stroke.
10.1007/s11655-014-1782-2
- Author:
Thanasekaran JAYAKUMAR
1
;
Antoinet Ramola ELIZEBETH
;
Ting-lin YEN
;
Joen-rong SHEU
Author Information
1. Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, 110, Taiwan, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Apoptosis;
drug effects;
Disease Models, Animal;
Drugs, Chinese Herbal;
chemistry;
pharmacology;
therapeutic use;
Humans;
Phytochemicals;
chemistry;
pharmacology;
therapeutic use;
Stroke;
drug therapy
- From:
Chinese journal of integrative medicine
2015;21(2):90-101
- CountryChina
- Language:English
-
Abstract:
Stroke is an important cause of mortality and morbidity worldwide but effective therapeutic strategy for the prevention of brain injury in patients with cerebral ischemia is lacking. Although tissue plasminogen activator has been used to treat stroke patients, this therapeutic strategy is confronted with ill side effects and is limited to patients within 3 h of a stroke. Due to the complexity of the events and the disappointing results from single agent trials, the combination of thrombolytic therapy and effective neural protection therapy may be an alternative strategy for patients with cerebral ischemia. Chinese medicine (CM) is the most widely practiced form of herbalism worldwide, as it is a sophisticated system of medical theory and practice that is specifically different from Western medicine. Most traditional therapeutic formulations consist of a combination of several drugs. The combination of multiple drugs is thought to maximize therapeutic efficacy by facilitating synergistic actions and preventing possible adverse effects while at the same time marking at multiple targets. CM has been labeled in ancient medicine systems as a treatment for various diseases associated with stroke. This review summarizes various CMs, bioactive compounds and their effects on cerebral ischemia.
